DK0969822T3 - Bestemmelse af et organs eller vævs tilbøjelighed til cancer ved bestemmelse af dets prægningsmønster - Google Patents

Bestemmelse af et organs eller vævs tilbøjelighed til cancer ved bestemmelse af dets prægningsmønster

Info

Publication number
DK0969822T3
DK0969822T3 DK97953486T DK97953486T DK0969822T3 DK 0969822 T3 DK0969822 T3 DK 0969822T3 DK 97953486 T DK97953486 T DK 97953486T DK 97953486 T DK97953486 T DK 97953486T DK 0969822 T3 DK0969822 T3 DK 0969822T3
Authority
DK
Denmark
Prior art keywords
imprinting
methods
restoring
normal
compositions
Prior art date
Application number
DK97953486T
Other languages
Danish (da)
English (en)
Inventor
Andrew P Feinberg
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of DK0969822T3 publication Critical patent/DK0969822T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK97953486T 1996-12-30 1997-12-29 Bestemmelse af et organs eller vævs tilbøjelighed til cancer ved bestemmelse af dets prægningsmønster DK0969822T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3409596P 1996-12-30 1996-12-30
PCT/US1997/023991 WO1998029108A2 (en) 1996-12-30 1997-12-29 Compositions and methods for restoring a normal pattern of imprinting to cells

Publications (1)

Publication Number Publication Date
DK0969822T3 true DK0969822T3 (da) 2003-07-21

Family

ID=21874277

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97953486T DK0969822T3 (da) 1996-12-30 1997-12-29 Bestemmelse af et organs eller vævs tilbøjelighed til cancer ved bestemmelse af dets prægningsmønster

Country Status (9)

Country Link
EP (1) EP0969822B1 (es)
JP (2) JP4913270B2 (es)
AT (1) ATE235190T1 (es)
AU (1) AU5722398A (es)
CA (1) CA2276306C (es)
DE (1) DE69720283T2 (es)
DK (1) DK0969822T3 (es)
ES (1) ES2195196T3 (es)
WO (1) WO1998029108A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803195B1 (en) * 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
GB0107267D0 (en) * 2001-03-23 2001-05-16 Babraham Inst Diagnostic method for determining the methylation state of cloned embryos
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2002952944A0 (en) * 2002-11-27 2002-12-12 Human Genetic Signatures Pty Ltd Restoration of methylation states in cells
DE602004028478D1 (de) 2003-06-17 2010-09-16 Human Genetic Signatures Pty Verfahren zur genomamplifikation
DE602004018801D1 (de) 2003-09-04 2009-02-12 Human Genetic Signatures Pty Nukleinsäurenachweistest
US8168777B2 (en) 2004-04-29 2012-05-01 Human Genetic Signatures Pty. Ltd. Bisulphite reagent treatment of nucleic acid
EP1794173B1 (en) 2004-09-10 2010-08-04 Human Genetic Signatures PTY Ltd Amplification blocker comprising intercalating nucleic acids (ina) containing intercalating pseudonucleotides (ipn)
DK1828411T3 (da) 2004-12-03 2013-02-18 Human Genetic Signatures Pty Fremgangsmåde til forenkling af mikrobielle nukleinsyrer ved kemisk modifikation af cytosiner
JP2008541705A (ja) 2005-05-26 2008-11-27 ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド 非標準塩基を含むプライマーを使用する等温鎖置換増幅
WO2007030882A1 (en) 2005-09-14 2007-03-22 Human Genetic Signatures Pty Ltd Assay for a health state
GB0607063D0 (en) 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
WO2009067743A1 (en) 2007-11-27 2009-06-04 Human Genetic Signatures Pty Ltd Enzymes for amplification and copying bisulphite modified nucleic acids
ES2613743T3 (es) 2011-09-07 2017-05-25 Human Genetic Signatures Pty Ltd Ensayo de detección molecular
WO2018214249A1 (zh) * 2017-05-22 2018-11-29 立森印迹诊断技术（无锡）有限公司 一种印记基因分级模型及其组成的系统和应用
WO2019218338A1 (zh) * 2018-05-18 2019-11-21 立森印迹诊断技术有限公司 通过活检细胞样本诊断癌症的方法
CN110714075B (zh) * 2018-07-13 2024-05-03 立森印迹诊断技术（无锡）有限公司 一种用于检测肺肿瘤良恶性程度的分级模型及其应用
CN110791563B (zh) * 2018-08-01 2024-02-09 立森印迹诊断技术（无锡）有限公司 一种用于检测甲状腺肿瘤良恶性程度的分级模型及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
CA2104964A1 (en) * 1991-02-28 1992-08-29 Ruth Sager Cancer diagnosis and therapy with tumor suppressor genes
CA2114728A1 (en) * 1991-08-08 1993-02-18 Tetsuro Ikekawa Carcinostatic compound and production thereof
US5356903A (en) * 1993-04-22 1994-10-18 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolines

Also Published As

Publication number Publication date
DE69720283T2 (de) 2004-01-29
EP0969822B1 (en) 2003-03-26
AU5722398A (en) 1998-07-31
CA2276306C (en) 2009-12-15
EP0969822A2 (en) 2000-01-12
JP2009072197A (ja) 2009-04-09
ATE235190T1 (de) 2003-04-15
CA2276306A1 (en) 1998-07-09
WO1998029108A3 (en) 1999-02-18
WO1998029108A2 (en) 1998-07-09
DE69720283D1 (de) 2003-04-30
JP4913270B2 (ja) 2012-04-11
ES2195196T3 (es) 2003-12-01
JP2001507703A (ja) 2001-06-12

Similar Documents

Publication Publication Date Title
DK0969822T3 (da) Bestemmelse af et organs eller vævs tilbøjelighed til cancer ved bestemmelse af dets prægningsmønster
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
DK0858330T3 (da) Præparater indeholdende derivater af hydroperoxyeicosatetraensyre og fremgangsmåder til anvendelse ved behandling af sygdom
HUP0302549A2 (hu) Eritropoietin-érzékeny sejtek, szövetek és szervek védelme, helyreállítása és növelése
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
RS49780B (sr) Primena derivata fumarne kiseline u transplantacionoj medicini
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
ATE237371T1 (de) Blasenmukosa mit zellen für die rekonstruktion von geweben
ES2139596T3 (es) Procedimiento para el diagnostico in vitro de anomalias cromosomicas relacionadas con la enfermedad cmt1a.
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
TR200200278T2 (tr) Kalsilitik bileşimler
DE69824017D1 (de) Vehikel zur gentherapie enthaltend dermales huellgewebe
WO1999045103A3 (en) Human spinal cord cell lines and methods of use therefor
DE69329760D1 (de) Behandlung von magen- und darmgeschwüren mit morphogenen
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
EP1332756A3 (en) Compositions and methods for restoring a normal pattern of imprinting to cells
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
BR9607178A (pt) Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit